Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Vera Therapeutics is a late-stage biotech developing disease-modifying treatments for severe immunological diseases, primarily focusing on IgA nephropathy (IgAN). Its lead candidate, atacicept, targets B-cell pathways to reduce autoantibodies and immune complexes, aiming to slow kidney disease progression. The company also holds rights to novel therapies for BK virus infections and other autoimmune kidney conditions, leveraging expertise in immunology and biologic drug development.
This description was generated via AI from an annual report. Updated about 1 year ago.